Search company, investor...

Paratek Pharmaceuticals

Founded Year



Loan | Alive

Total Raised


Last Raised

$60M | 2 yrs ago



About Paratek Pharmaceuticals

Paratek is a biopharmaceutical company focused on the development, and commercialization of innovative antibiotics. Paratek's lead product candidate, omadacycline, is a novel tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Omadacycline has Special Protocol Assessment agreements with the U.S. Food and Drug Administration for the phase 3 trials planned in ABSSSI and CABP.

Headquarters Location

75 Kneeland Street

Boston, Massachusetts, 02111,

United States


Missing: Paratek Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Paratek Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Paratek Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Paratek Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,898 items

Paratek Pharmaceuticals Patents

Paratek Pharmaceuticals has filed 1 patent.

The 3 most popular patent topics include:

  • Bacterial diseases
  • Antibiotics
  • NMDA receptor antagonists
patents chart

Application Date

Grant Date


Related Topics




Bacterial diseases, Rickettsioses, Biological weapons, Enterobacteriaceae, Zoonoses


Application Date


Grant Date



Related Topics

Bacterial diseases, Rickettsioses, Biological weapons, Enterobacteriaceae, Zoonoses



Latest Paratek Pharmaceuticals News

Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

Nov 21, 2022

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that Evan Loh, M.D., chief executive officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30 at 9:15 a.m. ET.

Paratek Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Paratek Pharmaceuticals founded?

    Paratek Pharmaceuticals was founded in 1996.

  • Where is Paratek Pharmaceuticals's headquarters?

    Paratek Pharmaceuticals's headquarters is located at 75 Kneeland Street, Boston.

  • What is Paratek Pharmaceuticals's latest funding round?

    Paratek Pharmaceuticals's latest funding round is Loan.

  • How much did Paratek Pharmaceuticals raise?

    Paratek Pharmaceuticals raised a total of $129.3M.

  • Who are the investors of Paratek Pharmaceuticals?

    Investors of Paratek Pharmaceuticals include CBC Group, HBM Healthcare Investments, Nomura Holdings, HBM Partners, Bio Fund Management and 21 more.

  • Who are Paratek Pharmaceuticals's competitors?

    Competitors of Paratek Pharmaceuticals include Advaxis, Cyclacel Pharmaceuticals, Molmed, Potentia Pharmaceuticals, Ampla Pharmaceuticals and 10 more.

Compare Paratek Pharmaceuticals to Competitors

Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.


Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

Longevica Logo

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

Qwell Pharmaceuticals

Qwell Pharmaceuticals is a biotechnology company focused on small molecule development primarily for oncology indications.

Arisyn Therapeutics

Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.

Logical Therapeutics

Logical Therapeutics is an early stage biotechnology company, developing medicines to treat diseases that are associated with poorly controlled or excessive inflammation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.